Oxford BioDynamics Advances Epigenetic Signatures for Breast Cancer, ALS

Oct 10, 2017

|

Premium

NEW YORK (GenomeWeb) – Oxford BioDynamics has made progress toward developing and validating epigenetic signatures for breast cancer and amyotrophic lateral sclerosis.

In recent weeks, the British company has announced the completion of two studies showcasing the ability of its EpiSwitch platform to diagnose and stage breast cancer and ALS patients. Also this month, the US Patent and Trademark Office granted Oxford BioDynamics a patent covering its EpiSwitch platform, which should support the firm as it looks to build its business in the US.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Recent Headlines from
Precision Oncology News

The Scan

Another Look

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

Some More Than Others

A new analysis finds some cancers receive more nonprofit dollars than others.

Gene Variant's Possible Role

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

Science Finds Sex-Biased Gene Expression in Mammals, More

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.

Featured White Papers

Genetic Testing as a Tool for Improving Care and Outcomes for Patients with Rare Inherited Retinal Diseases

Delivering Precision Health: the Role of Molecular Diagnostics

BlueBee Data Security & Compliance

Epigenomic Analysis of Sorted Retinal Ganglion Cells using ATAC-seq

Jul

23

Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.

Jul

24

Featured Webinar

Comparison of Group B Streptococcus Molecular Assays for Routine Screening in Pregnant Women

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul

25

Featured Webinar

Cell-free DNA Testing for Fetal Aneuploidy: Lessons Learned and Implications for Clinical Practice

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul

31

Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

Menu